Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COMMENTARY
COMMENTARY
- Current New Drug Development in the Japanese Pharmaceutical Industry（2）
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry（1）
February 11, 2008
- COMMENTARY／Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes？
February 4, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- OPINION／The East versus West Dilemma
January 28, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- No More Need for MRs？ -A Hell beyond the 2010 Crisis？-
January 14, 2008
- COMMENTARY／Year 2007 in Retrospect
December 24, 2007
- COMMENTARY／Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY／Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY：Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY：Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY／NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
- COMMENTARY／Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
- COMMENTARY／Market for Osteoporosis Drugs Booms
July 9, 2007
- COMMENTARY／Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
- COMMENTARY：Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
- COMMENTARY／Provisional Deliveries without Agreement on Prices
June 11, 2007
- COMMENTARY／Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…